Aclaris Therapeutics ACRS
$3.44 −$0.06 (-1.71%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.44 0.00%
Open$3.44
Prev close$3.50
Day range$3.40 – $3.55
Volume2.19M
Market cap$545.63M
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±6.6%last 16 reports
Closed higher4 of 1625% of the time
Best reaction+20.4%
Worst reaction-10.2%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2024/Q1 | 7 May 2024 | After Market | ±35.1% | -8.96% | Within range |
| 2023/Q1 | 8 May 2023 | Pre Market | ±12.5% | -6.46% | Within range |
| 2019/Q4 | 25 Feb 2020 | None | – | -10.22% | – |
| 2019/Q3 | 7 Nov 2019 | After Market | – | +15.38% | – |
| 2019/Q2 | 8 Aug 2019 | After Market | – | -9.08% | – |
| 2019/Q1 | 8 May 2019 | After Market | – | -9.82% | – |
| 2018/Q4 | 18 Mar 2019 | Pre Market | – | +20.43% | – |
| 2018/Q3 | 6 Nov 2018 | After Market | – | +2.30% | – |
| 2018/Q2 | 3 Aug 2018 | Pre Market | – | -1.52% | – |
| 2018/Q1 | 8 May 2018 | After Market | – | -1.96% | – |
| 2017/Q4 | 12 Mar 2018 | None | – | -7.19% | – |
| 2017/Q3 | 7 Nov 2017 | Pre Market | – | -8.45% | – |
| 2017/Q2 | 8 Aug 2017 | Pre Market | – | -1.00% | – |
| 2017/Q1 | 9 May 2017 | Pre Market | – | -0.52% | – |
| 2016/Q4 | 15 Mar 2017 | Pre Market | – | +0.56% | – |
| 2016/Q3 | 3 Nov 2016 | Pre Market | – | -1.71% | – |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$1.48M-55.1% YoY
Operating profit-$21.94M-28.7% YoY
Net profit-$18.51M-26.7% YoY
Diluted EPS-$0.12+0.0% YoY
Free cash flow-$24.09M-119.9% YoY
Operating cash flow-$24.08M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin5.8%
Operating margin-1,412.4%
Net margin-1,244.1%
Return on equity-55.5%
Return on assets-40.7%
Return on invested capital-60.2%
Current ratio5.09
Liabilities / assets22.8%
Cash & investments$114.29M
Net cash (debt)$114.29M
No comments yet — be the first to weigh in on ACRS.
Sign in to join the discussion.